📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. (2024)

First Author: Roos I

Attributed to: MRC Centre for Neuropsychiatric Genetics and Genomics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/13524585241267211

PubMed Identifier: 39087208

Publication URI: http://europepmc.org/abstract/MED/39087208

Type: Journal Article/Review

Volume: 30

Parent Publication: Multiple sclerosis (Houndmills, Basingstoke, England)

Issue: 9

ISSN: 1352-4585